Tazarotene
Other Antipsoriatics For Topical Use
Sold as ARAZLO · TAZORAC · DUOBRII
- Drug class
- Other Antipsoriatics For Topical Use
- Availability
- Prescription only
- Routes
- Cutaneous, Topical
- Markets covered
- 2
- Products on record
- 5
- FDA reports (12 mo)
- 54
Overview
Tazarotene is an active pharmaceutical ingredient in the Other Antipsoriatics For Topical Use group (D05AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 3 | November 13, 2025 |
| CA Canada | Health Canada | 2 | January 26, 2026 |
USUnited States· FDA
3 products
Uses
1% is a retinoid indicated for the topical treatment of plaque psoriasis. 1% is indicated for the topical treatment of acne vulgaris. 1% are indicated for the topical treatment of patients with plaque psoriasis. 1% is also indicated for the topical treatment of patients with acne vulgaris.
How to take
CACanada· Health Canada
2 products
Uses
DUOBRII (halobetasol propionate and tazarotene lotion), is indicated for: • Improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis. 1 Pediatrics Pediatrics (under the age of 18 years) The safety and efficacy of DUOBRII in pediatric patients have not been established; therefore, DUOBRII is not indicated for pediatric use (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics).
2 Geriatrics Geriatrics (> 65 years of age) A limited number of subjects aged > 65 years have been treated with DUOBRII in clinical trials, therefore the safety and efficacy have not been established in this patient population (see WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics).
How to take
Drug interactions
Known interactions involving Tazarotene. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 021744d1-a6d7-4a… · revised November 13, 2025 [PDF]
- [2]Health Canada (DPD) · 02499967 · revised October 27, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.